IPP Bureau
Dabur appoints Sriram Padmanabhan as Head of Health Care Business
By IPP Bureau - April 14, 2025
Padmanabhan brings over two decades of extensive experience in FMCG sector
Zyuds Lifesciences receives USFDA approval for DMD treatment drug
By IPP Bureau - April 14, 2025
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Aurobindo receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
By IPP Bureau - April 14, 2025
The product will be launched in Q1FY26
Nureca’s manufacturing subsidiary secures USFDA registration
By IPP Bureau - April 14, 2025
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
Healthcare Triangle appoints David Ayanoglou as CFO
By IPP Bureau - April 14, 2025
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
Aurolife Pharma gets 11 observations from USFDA for Raleigh plant
By IPP Bureau - April 14, 2025
The company does not expect this development to have any material impact on the current business operations
Fredun secures tender from TNMSC for supply of generic pharma products
By IPP Bureau - April 14, 2025
The supply of these goods is set to commence within the first quarter of FY26
Drager launches Atlan A100 anesthesia workstation in India
By IPP Bureau - April 12, 2025
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer
By IPP Bureau - April 12, 2025
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Morepen to add 1,000 medical representatives
By IPP Bureau - April 12, 2025
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
.jpg "Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension")
Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension
By IPP Bureau - April 12, 2025
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab
By IPP Bureau - April 11, 2025
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru
By IPP Bureau - April 11, 2025
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
US court lifts launch restrictions on Sun Pharma's autoimmune drug
By IPP Bureau - April 11, 2025
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Orchid Pharma to settle disputes with DBS Bank
By IPP Bureau - April 11, 2025
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
